Pilot Study of Swift Microwave Device for Onychomycosis

NCT ID: NCT05674747

Last Updated: 2024-11-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 39 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-03-27
• Study Completion Date: 2024-11-08

Brief Summary

This is an open, single site, pilot study in Canadian subjects diagnosed with mild to moderate toenail onychomycosis caused by dermatophytes. Three microwave treatment frequencies will be compared for efficacy and safety, evaluated by frequency of treatment-related adverse events, clinical improvement of a treated target toenail and inactivation/elimination of fungus in the target toenail. Outcomes will be evaluated at Month 6, Month 9 and Month 12 after initiation of treatments. Subjects not achieving 'temporary increase in clear nail' at Month 6 may receive extra microwave treatments to Month 9 or Month 12 to improve outcomes.

Detailed Description

This is an open, single site, pilot study in Canadian subjects diagnosed with mild to moderate toenail onychomycosis caused by dermatophytes. A total of 45 subjects will be enrolled in the study. All eligible subjects who provide written informed consent will be randomized to one of three groups (15 subjects in each group): Group A, B or C.

The treatment regimen for each group is as follows:

Group A: Subjects will receive treatment on Day 0 and then weekly in the first month followed by monthly treatment for a further 4 months (9 treatments).

Group B: Subjects will receive treatment on Day 0 and then every two weeks in the first month followed by monthly treatment for a further 4months (7 treatments).

Group C: Subjects will receive treatment on Day 0 and then once every two weeks in the first six months (12 treatments).

For all groups, patients not achieving 'FDA efficacy' levels at Month 6 End Visit and/or Month 9 End Visit will be offered continuation of treatments once monthly for 3 months to determine if additional treatment will continue to be safe and increase efficacy. Patients may refuse additional treatment, while continuing in safety follow-up to Months 9/12.

Subjects will be followed up every 3 months for safety and efficacy to Month 12, and at any treatment intervals occurring between these main visits. Efficacy will be assessed by changes in affected nail area and length, both in clinic and through photos. Mycology sampling will be performed at pre-determined intervals to assess fungal presence and viability post-treatment.

Conditions

Onychomycosis of Toenail

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Group A-Weekly x 4wk

Subjects will receive treatment on Day 0 and then weekly in the first month followed by monthly treatment to Month 6 (9 treatments).

Subjects who do not meet the 'temporary increase in clear nail' criteria at Month 6 and/or Month 9 will be offered once monthly treatment for 3 additional months.

Group Type: EXPERIMENTAL

Swift Microwave treatment - weekly x 4wks

Intervention Type: DEVICE

Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.

Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions).

Group B-Biweekly x4wk

Subjects will receive treatment on Day 0 and then every two weeks in the first month followed by monthly treatment to Month 6 (7 treatments).

Subjects who do not meet the 'temporary increase in clear nail' criteria at Month 6 and/or Month 9 will be offered once monthly treatment for 3 additional months.

Group Type: EXPERIMENTAL

Swift Microwave treatment - Every other week x 4wks

Intervention Type: DEVICE

Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.

Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions).

Group C-Biweekly x 24wks

Subjects will receive treatment on Day 0 and then once every two weeks in the first six months (12 treatments).

Subjects who do not meet the 'temporary increase in clear nail' criteria at Month 6 and/or Month 9 will be offered once monthly treatment for 3 additional months.

Group Type: EXPERIMENTAL

Swift Microwave treatment - Every other week x 24wks

Intervention Type: DEVICE

Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.

Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions).

Interventions

Swift Microwave treatment - weekly x 4wks

Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.

Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions).

Intervention Type: DEVICE

Swift Microwave treatment - Every other week x 4wks

Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.

Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions).

Intervention Type: DEVICE

Swift Microwave treatment - Every other week x 24wks

Swift device set up to 7-9 Watts applied locally for up to a 3 second burst to the toenail.

Start at 9 Watts and apply locally for up to a 3 second burst; adjust the dose and duration as is tolerable for the subject. Repeat on the infected parts of the nail as is tolerable for the subjects ( up to 5 repetitions).

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Provide written informed consent.

2. Aged 18 years and above.

3. Not Pregnant or breast feeding.

4. Distal subungual onychomycosis (DSO) in a great toenail.

5. One great toenail as a target for treatment having at least 20% involvement of the nail area and no more than 75% involvement of the nail area.

6. Target toenail thickness 3mm or less.

7. No area of infection < 3mm from the proximal nail fold.

8. Toenail for treatment with fungal infection confirmed by detection of a dermatophyte organism (i.e. Trichophyton rubrum).

9. No more than 4 toenails showing visual signs of onychomycosis, including the target toenail.

10. Subject agrees not to have any oral antifungal treatment or topical onychomycosis treatment during the study.

11. Able to perform study assessments.

Exclusion Criteria

1. Proximal subungual onychomycosis (PSO).

2. Superficial white onychomycosis (SWO).

3. Nail changes that appear as parallel lines, small pinpoint depressions, brown spots, black or brown linear streaks, complete yellowing of all nails without textural change, green debris below the nail or notches in the nail margin ('non-onychomycotic dystrophy').

4. Nails infected by rare fungal species or non-fungal organisms such as mould or bacteria

5. "Spike" of onychomycosis extending to <3mm from the eponychium (proximal nail fold) of the target toenail.

6. Presence of dermatophytoma (defined as thick masses of fungal hyphae and necrotic keratin between the nail plate and nail bed) on the target nail.

7. Patients diagnosed with Diabetes Mellitus (types I and II).

8. Peripheral vascular disease.

9. Recurrent cellulitis.

10. Lymphatic insufficiency.

11. Immunocompromised (due to underlying medical disorders or to immunosuppressive treatments).

12. Exhibit an increased risk of bacterial infections due to skin breakdown induced by a fungus

13. Have a current infection or condition of the feet (fungal or otherwise) which may require antifungal or antibacterial treatment during therapy that may confound the study data.

14. Nails for treatment involving the lunula.

15. Co-morbidities including psoriasis, lichen planus or other medical conditions known to induce nail changes.

16. Patients with trauma from ill-fitting shoes, running or overly-aggressive nail care.

17. Subjects that have podiatric/ nursing nail care on a regular basis.

18. Previous target toenail surgery with any residual disfigurement.

19. Nails infected with Candida.

20. Any uncontrolled condition which, in the opinion of the Investigator, may put the subjects at undue risk of adverse effects during the study.

21. Subjects who have had any topical onychomycosis medication for at least 3-months prior to start of treatment or oral antifungal medication at least 6-months prior to study treatment.

22. Implantable Cardioverter Defibrillator (ICD), pacemaker or other implantable device.

23. Metal implants at the site of treatment (within foot or ankle).

24. Severe moccasin tinea pedis.

25. Known allergy or intolerance to microwave therapy.

26. Subject who has had any topical metallic or ionic treatment (e.g, aluminum chloride, silver nitrate) in the target or treated toenail areas within the last 6 months and agrees not to use any during the study.

27. Current participation in a non-observational trial, or have done so within the last 30-days.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Emblation Limited

INDUSTRY

Sponsor Role: collaborator

Mediprobe Research Inc.

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Aditya Gupta, MD,PhD

Role: PRINCIPAL_INVESTIGATOR

Mediprobe Research Inc.

Locations

Mediprobe Research Inc

London, Ontario, Canada

Countries

Canada

References

Gupta AK, Cooper EA, Wang T. Safety and efficacy of the swift microwave device in patients with mild-to-moderate onychomycosis: Protocol of an open-label, randomized, dose-finding pilot study. Skin Health Dis. 2024 Oct 10;4(6):e455. doi: 10.1002/ski2.455. eCollection 2024 Dec.

Reference Type: DERIVED

PMID: 39624747 (View on PubMed)

Other Identifiers

FN1p

Identifier Type: -

Identifier Source: org_study_id